Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CAI
SELLCaris Life Sciences, Inc. · Healthcare · United States · $4.4B · Avg Vol: $50M/d
COMPANY DESCRIPTION
Caris Life Sciences, Inc. is a precision oncology company offering molecular profiling services and AI-driven diagnostics for cancer, guiding personalized treatment decisions. Its proprietary AI platform (Caris AI) and extensive real-world clinical data set allow for deep insights into tumor biology, differentiating its diagnostic capabilities. Caris is a pioneer in precision medicine, advancing cancer diagnostics and therapeutic selection through advanced molecular profiling and artificial intelligence.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 258.5M | 306.1M | 412.3M | 812.0M | 46.5% | 907.3M | 1.0B | 1.2B | 21.5% |
| EPS | -1.57 | -1.82 | -1.36 | -3.22 | — | -2.61 | — | — | — |
| Shares | 277.9M | 277.9M | 277.9M | 282.5M | +1.7% | 282.7M | — | — | — |
| Debt | 270.9M | 217.1M | 424.3M | 427.7M | 16.4% | 431.0M | — | — | — |
| Equity | -1.7B | -2.1B | -2.5B | 577.3M | — | — | — | — | — |
| Op CF | -285.7M | -276.1M | -245.2M | 83.2M | — | 147.4M | — | — | — |
| Inv CF | -283.0M | 214.8M | 52.9M | -16.3M | — | — | — | — | — |
| Fin CF | 10.4M | 10.1M | 200.3M | 665.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CAI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CAI | Caris Life Sciences, Inc.(you) | $4.4B | 27 | SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 27 | SELL |
| TNGX | Tango Therapeutics, Inc. | $4.3B | 29 | SELL |
| EWTX | Edgewise Therapeutics, Inc. | $4.4B | 30 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 27 | SELL |
| RLAY | Relay Therapeutics, Inc. | $4.0B | 31 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 24 | SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 20 | SELL |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.4B | 30 | SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%